IP Verse

Pfizer Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Pfizer Inc.

Patent Number:
EP3227333
Title:
Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases
Applicant:
BRISTOL-MYERS SQUIBB COMPANY
Opposition Date:
May 16, 2024
Patent Number:
EP3007724
Title:
Compositions And Methods Of Immunizing Against C. Difficile
Applicant:
SANOFI PASTEUR INC.
Opposition Date:
Apr 5, 2024
Patent Number:
EP4108769
Title:
A Method For Producing And Purifying Rna, Comprising At Least One Step Of Tangential Flow Filtration
Applicant:
CUREVAC MANUFACTURING GMBH
Opposition Date:
Feb 29, 2024
Patent Number:
EP3625345
Title:
Modified Messenger Rna Comprising Functional Rna Elements
Applicant:
MODERNATX, INC.
Opposition Date:
Feb 26, 2024
Patent Number:
EP4023755
Title:
Artificial Nucleic Acid Molecules For Improved Protein Expression
Applicant:
CUREVAC AG
Opposition Date:
Jan 26, 2024
Patent Number:
EP3581650
Title:
Factor Ix Polypeptide Mutant, Its Uses And A Method For Its Production
Applicant:
UNIQURE BIOPHARMA B.V.
Opposition Date:
Sep 27, 2023
Patent Number:
EP3355919
Title:
Combination Therapy Using Inhibitors Of Human Growth And Differentiation Factor 15 (Gdf-15) And Immune Checkpoint Blockers
Applicant:
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
Opposition Date:
Sep 6, 2023
Patent Number:
EP3708668
Title:
Artificial Nucleic Acid Molecules For Improved Protein Expression
Applicant:
CUREVAC AG
Opposition Date:
Apr 27, 2023
Patent Number:
EP3590949
Title:
Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses Thereof
Applicant:
MODERNATX, INC.
Opposition Date:
Feb 17, 2023
Patent Number:
EP3718565
Title:
Respiratory Virus Vaccines
Applicant:
MODERNATX, INC.
Opposition Date:
Jan 27, 2023

Latest patents of Pfizer Inc. opposed by its competitors

Patent:
EP3583947
Grant Date:
Oct 11, 2023
Title:
Streptococcus Pneumoniae Capsular Polysaccharides And Conjugates Thereof
Oppositions:
2
Patent:
EP3555064
Grant Date:
Mar 1, 2023
Title:
Glp-1 Receptor Agonists And Uses Thereof
Oppositions:
1
Patent:
EP3191461
Grant Date:
Nov 3, 2021
Title:
Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole
Oppositions:
5
Patent:
EP3498734
Grant Date:
Sep 1, 2021
Title:
Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer
Oppositions:
7
Patent:
EP3431475
Grant Date:
Apr 7, 2021
Title:
Solid Forms Of A Selective Cdk4/6 Inhibitor
Oppositions:
4
Patent:
EP2968155
Grant Date:
Mar 3, 2021
Title:
Tofacitinib Oral Sustained Release Dosage Forms
Oppositions:
6
Patent:
EP3096785
Grant Date:
Sep 9, 2020
Title:
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens And Uses Thereof
Oppositions:
3
Patent:
EP3246021
Grant Date:
Nov 13, 2019
Title:
Apixaban Formulations
Oppositions:
12
Patent:
EP3302565
Grant Date:
Nov 6, 2019
Title:
Solid Dosage Forms Of Palbociclib
Oppositions:
6
Patent:
EP3251660
Grant Date:
Oct 16, 2019
Title:
Apixaban Formulations
Oppositions:
10

Competitors of Pfizer Inc.

MODERNATX, INC.

STADA ARZNEIMITTEL AG

GENERICS (U.K.) LIMITED

Want to track Pfizer Inc.?

Feel free to send us a message here and we will get back to you